.png)
Argenx stays on a roll with Vyvgart, gaining FDA nod for at-home prefilled syringe
Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2.2 billion in sales last year, argenx has scored FDA approval for a new formulation of the treatment which gives patients the option of administering it at home.
Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2.2 billion in sales last year, argenx has scored FDA approval for a new formulation of the treatment which gives patients the option of administering it at home.
